Results 31 to 40 of about 70,416 (256)

Effect of sorafenib on murine liver regeneration [PDF]

, 2011
Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib prolongs survival of patients with advanced disease and is approved for the systemic treatment of unresectable HCC.
Pamela Romanque, Dufour, Jean-Francois F., Romanque Ulloa, Pamela, Romanque, Pamela, Caroline Hora, Jean-François F. Dufour, Hora, Caroline, Dufour, Jean-François   +7 more
core   +1 more source

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BMC Cancer, 2018
Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications.
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang   +9 more
doaj   +1 more source

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

Cancer Biology & Medicine, 2022
Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance.
Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen, Jinbao Liu   +12 more
doaj   +1 more source

Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model

, 2020
Sorafenib, a multitargeted kinase inhibitor, has been reported to elicit a limited therapeutic effect in hepatocellular carcinoma (HCC). Currently, phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is emerging as a ...
Ji-Min Zhu, Ji-Min Zhu (424921), Xiang-Nan Yu (8658444), Jie Liu, Jie Liu (15128), Xi-Zhong Shen (157536), Yong Deng, Xiang-Nan Yu, Yu-Hao Li, Ling Dong (470979), Ling Dong, Chang-Feng Zhu, Guang-Cong Zhang (8658447), Tao-Tao Liu, Guang-Cong Zhang, Chang-Feng Zhu (8658450), Xi-Zhong Shen, Tao-Tao Liu (424922), Yong Deng (422212), Yu-Hao Li (2086555)   +19 more
core   +1 more source

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

Frontiers in Pharmacology, 2020
PurposeTo investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).Materials and MethodsThis retrospective study examined 50 ...
Ying Wu, Ying Wu, Han Qi, Han Qi, Fei Cao, Fei Cao, Lujun Shen, Lujun Shen, Shuanggang Chen, Shuanggang Chen, Lin Xie, Lin Xie, Tao Huang, Tao Huang, Ze Song, Danyang Zhou, Danyang Zhou, Weijun Fan, Weijun Fan   +18 more
doaj   +1 more source

Anti-angiogenesis in hepatocellular carcinoma treatment : current evidence and future perspectives [PDF]

, 2011
Hepatocellular carcinoma (HCC) is among the most common cancer diseases worldwide. Arterial hypervascularisation is an essential step for HCC tumorigenesis and can be targeted by transarterial chemoembolization (TACE).
Trojan, Jörg, Welker, Martin-Walter
core   +1 more source

Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.

PLoS ONE, 2021
Background and aimAs a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems.
Luping Gao, Yuji Morine, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki, Mitsuo Shimada   +8 more
doaj   +1 more source

Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model [PDF]

, 2015
PURPOSEUse of oral sorafenib, an antiangiogenic chemotherapeutic agent for hepatocellular carcinoma (HCC), is limited by an unfavorable side effect profile.
Leigh C. Casadaban,, Zane Z. Hauck,, Ron C. Gaba, Ahmad Parvinian,, Richard B. van Breemen,   +4 more
core   +1 more source

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats

Molecules, 2017
Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). In Asia, patients with HCC are potentially treated with the combination of sorafenib and Chinese herbal medicines to improve the efficiency and reduce the side ...
Chin-Tsung Ting, Yung-Yi Cheng, Tung-Hu Tsai   +2 more
doaj   +1 more source

HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters

International Journal of Genomics, 2022
Hepatocellular carcinoma (HCC) represents a common malignancy, and mechanisms of acquired sorafenib resistance during the treatment of HCC patients remain elusive.
Xian Zhu, Yinfang Zhang, Yafei Wu, Wenjing Diao, Guilong Deng, Qin Li, Chuanxing Wu   +6 more
doaj   +1 more source